![ASCO 2022 Conference Coverage](http://media.vumedi.com/thumbs/channel_logo/2022/5/eadfa937-de35-4504-be38-58654669525f.png.200x0_q85.png)
ASCO 2022 Conference Coverage
Playback speed
10 seconds
ASCO 2022 on a Regional Subgroup Analysis of the Phase 3 TOPAZ-1 Study of Durvalumab + Gemcitabine & Cisplatin in Advanced Biliary Tract Cancer
By
ASCO 2022 Conference Coverage
FEATURING
Arndt Vogel
By
ASCO 2022 Conference Coverage
FEATURING
Arndt Vogel
144 views
June 15, 2022
Login to view comments.
Click here to Login
GI